Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Schiff

Showing results (1-10 of 83) with videos related to

Pageof 9
Sort By:
Current Treatment Options in Rheumatology|September 23, 2017
Co-stimulation Therapy in Rheumatoid Arthritis: Today and TomorrowMichael Schiff
Clinical Therapeutics|July 11, 2003
A rationale for the use of summary measurements for the assessment of the effects of rheumatoid arthritis therapiesMichael Schiff
Rheumatology (Oxford, England)|March 7, 2013
Subcutaneous abatacept for the treatment of rheumatoid arthritisMichael Schiff
Rheumatology (Oxford, England)|September 30, 2010
Abatacept treatment for rheumatoid arthritisMichael Schiff
Digestion|November 7, 2019
Combination Treatment with Antibiotics and Glucocorticosteroids for Severe Ischemic ColitisWolfgang Kruis, Michael Schiff
Expert Review of Gastroenterology & Hepatology|December 14, 2011
HZT-501 (DUEXIS(®); ibuprofen 800 mg/famotidine 26.6 mg) gastrointestinal protection in the treatment of the signs and symptoms of rheumatoid arthritis and osteoarthritisMichael Schiff, David Peura
The Journal of Rheumatology|July 2, 2004
Comparison of the analgesic efficacy and safety of nonprescription doses of naproxen sodium and Ibuprofen in the treatment of osteoarthritis of the kneeMichael Schiff, Milos Minic
Clinical Rheumatology|January 26, 2010
Evaluation of abatacept in biologic-naïve patients with active rheumatoid arthritisMichael Schiff, Louis Bessette
Biologics : Targets & Therapy|March 7, 2014
A critical evaluation of the role of subcutaneous abatacept in the treatment of rheumatoid arthritis: patient considerationsAlvin F Wells, Nicole Jodat, Michael Schiff
Clinical and Experimental Rheumatology|August 28, 2018
Can switching to abatacept therapy in patients with rheumatoid arthritis on background methotrexate reverse TNF-inhibitor-induced antinuclear autoantibody/double-stranded DNA autoantibody conversion? An analysis of the AMPLE and ATTEST trialsMaya H Buch, Alyssa Johnsen, Michael Schiff
Pageof 9

Showing results (1-10 of 83) with videos related to

Sort By:
Pageof 9
Current Treatment Options in Rheumatology|September 23, 2017
Co-stimulation Therapy in Rheumatoid Arthritis: Today and TomorrowMichael Schiff
Clinical Therapeutics|July 11, 2003
A rationale for the use of summary measurements for the assessment of the effects of rheumatoid arthritis therapiesMichael Schiff
Rheumatology (Oxford, England)|March 7, 2013
Subcutaneous abatacept for the treatment of rheumatoid arthritisMichael Schiff
Rheumatology (Oxford, England)|September 30, 2010
Abatacept treatment for rheumatoid arthritisMichael Schiff
Digestion|November 7, 2019
Combination Treatment with Antibiotics and Glucocorticosteroids for Severe Ischemic ColitisWolfgang Kruis, Michael Schiff
Expert Review of Gastroenterology & Hepatology|December 14, 2011
HZT-501 (DUEXIS(®); ibuprofen 800 mg/famotidine 26.6 mg) gastrointestinal protection in the treatment of the signs and symptoms of rheumatoid arthritis and osteoarthritisMichael Schiff, David Peura
The Journal of Rheumatology|July 2, 2004
Comparison of the analgesic efficacy and safety of nonprescription doses of naproxen sodium and Ibuprofen in the treatment of osteoarthritis of the kneeMichael Schiff, Milos Minic
Clinical Rheumatology|January 26, 2010
Evaluation of abatacept in biologic-naïve patients with active rheumatoid arthritisMichael Schiff, Louis Bessette
Biologics : Targets & Therapy|March 7, 2014
A critical evaluation of the role of subcutaneous abatacept in the treatment of rheumatoid arthritis: patient considerationsAlvin F Wells, Nicole Jodat, Michael Schiff
Clinical and Experimental Rheumatology|August 28, 2018
Can switching to abatacept therapy in patients with rheumatoid arthritis on background methotrexate reverse TNF-inhibitor-induced antinuclear autoantibody/double-stranded DNA autoantibody conversion? An analysis of the AMPLE and ATTEST trialsMaya H Buch, Alyssa Johnsen, Michael Schiff
Pageof 9